Eli Lilly & Co.

1. 01

   Ahead of SPY and its sector fund XLV over 1 year

   1 month: +23.3% (SPY −2.6%, XLV +9.9%). 3 months: +26.3% (SPY −2.2%, XLV +13.5%). 1 year: +57.2% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: LLY, SPY and XLV · as of 3 Nov 2026

2. 02

   2.8% below its 52-week high

   Closed at $1,409.38 on 3 Nov 2026: 2.8% below the 52-week high of $1,449.68 (30 Oct 2026) and 65.7% above the low of $850.51 (29 Apr 2026).

   Daily price bars, split-adjusted · as of 3 Nov 2026

3. 03

   Above its 50- and 200-day averages

   The 3 Nov 2026 close of $1,409.38 was 17.1% above its 50-day average ($1,203.50) and 28.7% above its 200-day average ($1,094.99). It has closed above the 200-day for 130 sessions, since 30 Apr 2026. The 50-day average crossed above the 200-day on 5 Nov 2025, 249 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026

4. 04

   Next ex-dividend date: 13 Nov 2026

   $1.73 a share, payable 10 Dec 2026; unchanged from the previous payment (ex-date 14 Aug 2026).

   Corporate actions record · as of 4 Nov 2026

5. 05

   RSI(14) at 75.8, 70 or above

   The 14-session relative strength index closed at 75.8 on 3 Nov 2026, its 4th session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.

   Daily closes, split-adjusted; Wilder's 14-session RSI · as of 3 Nov 2026

At the 3 Nov 2026 close